Obinituzumab, a humanized monoclonal against CD20 approved for chronic lymphocytic leukemia, causes profound B-cell depletion; the drug, recently tried in two anti-MAG neuropathy patients resistant or partially responding to rituximab did not show efficacy, in spite of reducing the IgM levels and anti-MAG titers.73 Belimumab against the B-lymphocyte stimulator BLyS, approved for lupus, may be another alternative, although its failure in MS and myasthenia gravis, lowers its priority status.36,54. This evidence concerns the gene TNFSF13B and myeloid sarcoma.